Apollomics Inc. shares have been volatile, with a drop of over 75% in the last month. The company announced a report by the Veneto Institute of Oncology on the efficacy of vebreltinib for GBM with PTPRZ-MET fusion. The patient reported an impressive Partial Response after 8 weeks of treatment. Apollomics also presented vebreltinib efficacy and safety data from the KUNPENG clinical trial. Shares of Apollomics are up on heavy trading volume, with more than 67 million shares traded, far exceeding the stock's 100-day average volume of less than 53 thousand shares.